NasdaqCM - Nasdaq Real Time Price USD

NRx Pharmaceuticals, Inc. (NRXPW)

Compare
0.0550 0.0000 (0.00%)
At close: October 29 at 4:00 PM EDT
Loading Chart for NRXPW
DELL
  • Previous Close 0.0550
  • Open 0.0550
  • Bid --
  • Ask --
  • Day's Range 0.0550 - 0.0550
  • 52 Week Range 0.0550 - 0.0550
  • Volume 355
  • Avg. Volume --
  • Market Cap (intraday) --
  • Beta (5Y Monthly) 1.25
  • PE Ratio (TTM) --
  • EPS (TTM) -6.2470
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

www.nrxpharma.com

--

Full Time Employees

--

Fiscal Year Ends

Recent News: NRXPW

View More

Compare To: NRXPW

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NRXPW

View More

Valuation Measures

Annual
As of
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -115.97%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -24.83M

  • Diluted EPS (ttm)

    -6.2470

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.9M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -7.35M

Company Insights: NRXPW

People Also Watch